BOSUTINIB Drug Patent Profile
✉ Email this page to a colleague
When do Bosutinib patents expire, and when can generic versions of Bosutinib launch?
Bosutinib is a drug marketed by Alembic and is included in one NDA.
The generic ingredient in BOSUTINIB is bosutinib monohydrate. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the bosutinib monohydrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bosutinib
A generic version of BOSUTINIB was approved as bosutinib monohydrate by ALEMBIC on May 23rd, 2025.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BOSUTINIB?
- What are the global sales for BOSUTINIB?
- What is Average Wholesale Price for BOSUTINIB?
Summary for BOSUTINIB
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | BOSUTINIB at DailyMed |
US Patents and Regulatory Information for BOSUTINIB
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic | BOSUTINIB MONOHYDRATE | bosutinib monohydrate | TABLET;ORAL | 209543-001 | May 23, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Alembic | BOSUTINIB MONOHYDRATE | bosutinib monohydrate | TABLET;ORAL | 209543-002 | May 23, 2025 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
